HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Myocardial phospholipases A(2) and their membrane substrates.

Abstract
Many of the adverse sequelae of acute myocardial ischemia result from the degradation of sarcolemmal phospholipid constituents mediated by the activation of intracellular phospholipases. The consequent deleterious changes in sarcolemmal membrane properties precipitate ischemic membrane dysfunction resulting in electrophysiologic alterations and myocytic cell death. In myocardium, the overwhelming majority of phospholipase activity is catalyzed by a novel class of calcium-independent plasmalogen-selective phospholipases A(2) that is rapidly and reversibly activated within minutes of myocardial ischemia. Elucidation of the molecular mechanisms underlying the regulation of these phospholipases A(2) will define novel therapeutic targets that can potentially be pharmacologically manipulated to attenuate the deleterious effects of ischemia and reperfusion on myocardial function.
AuthorsR W Gross
JournalTrends in cardiovascular medicine (Trends Cardiovasc Med) 1992 May-Jun Vol. 2 Issue 3 Pg. 115-21 ISSN: 1050-1738 [Print] United States
PMID21239270 (Publication Type: Journal Article)
CopyrightCopyright © 1992. Published by Elsevier Inc.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: